The development of targeted molecular therapy to inhibit vascular endothelial growth factor (VEGF) has revolutionized the treatment and visual prognosis of retinal diseases such as diabetic retinopathy and age-related macular degeneration, as well as macular edema and retinal vein occlusion through performing intravitreal injections (IVIs) of these drugs [1, 2]. This evidence concerns the gene VEGFA and retinal vein occlusion.